Trial Profile

A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Domvanalimab (Primary) ; Etrumadenant (Primary) ; Zimberelimab (Primary)
Indications Brain metastases; Meningeal carcinomatosis; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use

05 Nov 2025 Planned End Date changed from 31 Dec 2029 to 30 Apr 2026.
05 Nov 2025 Planned primary completion date changed from 31 Oct 2025 to 30 Apr 2026.
04 Jul 2025 Planned End Date changed from 30 Sep 2029 to 31 Dec 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com